Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia

JCI Insight

Volumn 1, Issue 15, 2016, Pages

  Jourdain, Vincent A ^a   Tang, Chris C ^a   Holtbernd, Florian ^a   Dresel, Christian ^a   Choi, Yoon Young ^a   Ma, Yilong ^a   Dhawan, Vijay ^a   Eidelberg, David ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85055600504     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.86615     Document Type: Article

References (57)

1. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670–1683.
2. Fahn S, Poewe W. Levodopa: 50 years of a revolutionary drug for Parkinson disease. Mov Disord. 2015;30(1):1–3.
3. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol. 2006;63(2):205–209.
4. Cenci MA. Presynaptic mechanisms of l-dopa-induced dyskinesia: the findings, the debate, and the therapeutic implications. Front Neurol. 2014;5:242.
5. Stoessl AJ. Central pharmacokinetics of levodopa: lessons from imaging studies. Mov Disord. 2015;30(1):73–79.
6. Politis M, et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients. J Clin Invest. 2014;124(3):1340–1349.
7. Baron JC, et al. Local interrelationships of cerebral oxygen consumption and glucose utilization in normal subjects and in ischemic stroke patients: a positron tomography study. J Cereb Blood Flow Metab. 1984;4(2):140–149.
8. Herscovitch P. Can [15O]water be used to evaluate drugs? J Clin Pharmacol. 2001;Suppl:11S–20S.
9. Clarke DE, and Sokoloff L. Circulation and energy metabolism of the brain. In Siegel GJ, ed. Basic Neurochemistry. Philadelphia, Pennsylvania, USA: Lippincott; 1999. http://www.ncbi.nlm.nih.gov/books/NBK20413. Accessed August 19, 2016.
10. Dhawan V, Tang CC, Ma Y, Spetsieris P, Eidelberg D. Abnormal network topographies and changes in global activity: absence of a causal relationship. Neuroimage. 2012;63(4):1827–1832.
11. Spetsieris PG, Eidelberg D. Scaled subprofile modeling of resting state imaging data in Parkinson’s disease: methodological issues. Neuroimage. 2011;54(4):2899–2914.
12. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci. 2009;32(10):548–557.
13. Niethammer M, Eidelberg D. Metabolic brain networks in translational neurology: concepts and applications. Ann Neurol. 2012;72(5):635–647.
14. Tang CC, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 2010;9(2):149–158.
15. Ko JH, et al. Network modulation following sham surgery in Parkinson’s disease. J Clin Invest. 2014;124(8):3656–3666.
16. Asanuma K, et al. Network modulation in the treatment of Parkinson’s disease. Brain. 2006;129(Pt 10):2667–2678.
17. Hirano S, et al. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson’s disease. J Neurosci. 2008;28(16):4201–4209.
18. Afonso-Oramas D, et al. Striatal vessels receive phosphorylated tyrosine hydroxylase-rich innervation from midbrain dopaminergic neurons. Front Neuroanat. 2014;8:84.
19. Edvinsson L, Krause D. Catecholamines. In Edvinsson L, Krause D, eds. Cerebral Blood Flow and Metabolism. Philadelphia, Pennsylvania, USA: Lippincott Wiliams & Wilkins; 2002: 191–211.
20. Ohlin KE, Sebastianutto I, Adkins CE, Lundblad C, Lockman PR, Cenci MA. Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson’s disease. Neuroimage. 2012;61(1):228–239.
21. Tang CC, Poston KL, Dhawan V, Eidelberg D. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson’s disease. J Neurosci. 2010;30(3):1049–1056.
22. Holtbernd F, et al. Dopaminergic correlates of metabolic network activity in Parkinson’s disease. Hum Brain Mapp. 2015;36(9):3575–3585.
23. Moore RY, Whone AL, Brooks DJ. Extrastriatal monoamine neuron function in Parkinson’s disease: an 18F-dopa PET study. Neurobiol Dis. 2008;29(3):381–390.
24. de la Fuente-Fernández R, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson’s disease: implications for dyskinesias. Brain. 2004;127(Pt 12):2747–2754.
25. Ishikawa T, et al. Clinical significance of striatal DOPA decarboxylase activity in Parkinson’s disease. J Nucl Med. 1996;37(2):216–222.
26. 11C]DASB PET study in Parkinson’s disease. Neuroimage. 2012;59(2):1080–1084.
27. Feigin A, et al. Metabolic correlates of levodopa response in Parkinson’s disease. Neurology. 2001;57(11):2083–2088.
28. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson’s disease: clinical and pharmacological classification. Mov Disord. 1992;7(2):117–124.
29. Goetz CG, et al. Placebo response in Parkinson’s disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008;23(5):690–699.
30. Sokoloff L. Energetics of functional activation in neural tissues. Neurochem Res. 1999;24(2):321–329.
31. Lin TP, et al. Metabolic correlates of subthalamic nucleus activity in Parkinson’s disease. Brain. 2008;131(Pt 5):1373–1380.
32. Lee JY, Seo S, Lee JS, Kim HJ, Kim YK, Jeon BS. Putaminal serotonergic innervation: monitoring dyskinesia risk in Parkinson disease. Neurology. 2015;85(10):853–860.
33. Halje P, Tamtè M, Richter U, Mohammed M, Cenci MA, Petersson P. Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations. J Neurosci. 2012;32(47):16541–16551.
34. Cenci MA, Konradi C. Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res. 2010;183:209–233.
35. Westin JE, et al. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. J Neurosci. 2006;26(37):9448–9461.
36. Lindgren HS, Ohlin KE, Cenci MA. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson’s disease. Neuropsychopharmacology. 2009;34(12):2477–2488.
37. Ohlin KE, et al. Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain. 2011;134(Pt 8):2339–2357.
38. Adair TH, Montani JP. Angiogenesis. San Rafael, California, USA: Morgan & Claypool Life Sciences; 2010. http://www.ncbi.nlm.nih.gov/books/NBK53242. Accessed August 19, 2016.
39. Vogel J, Gehrig M, Kuschinsky W, Marti HH. Massive inborn angiogenesis in the brain scarcely raises cerebral blood flow. J Cereb Blood Flow Metab. 2004;24(8):849–859.
40. Filosa JA. Vascular tone and neurovascular coupling: considerations toward an improved in vitro model. Front Neuroenergetics. 2010;2.
41. Uc EY, Dienel GA, Cruz NF, Harik SI. beta-Adrenergics enhance brain extraction of levodopa. Mov Disord. 2002;17(1):54–59.
42. Gray MT, Woulfe JM. Striatal blood-brain barrier permeability in Parkinson’s disease. J Cereb Blood Flow Metab. 2015;35(5):747–750.
43. Cilia R, et al. The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137(Pt 10):2731–2742.
44. Holtbernd F, et al. Abnormal metabolic network activity in REM sleep behavior disorder. Neurology. 2014;82(7):620–627.
45. Wu P, et al. Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder. Brain. 2014;137(Pt 12):3122–3128.
46. Spetsieris PG, et al. Metabolic resting-state brain networks in health and disease. Proc Natl Acad Sci USA. 2015;112(8):2563–2568.
47. Lewitt PA, et al. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology. 2012;79(2):163–169.
48. Perez XA. Preclinical evidence for a role of the nicotinic cholinergic system in Parkinson’s disease. Neuropsychol Rev. 2015;25(4):371–383.
49. Trost M, et al. Network modulation by the subthalamic nucleus in the treatment of Parkinson’s disease. Neuroimage. 2006;31(1):301–307.
50. Wang J, Ma Y, Huang Z, Sun B, Guan Y, Zuo C. Modulation of metabolic brain function by bilateral subthalamic nucleus stimulation in the treatment of Parkinson’s disease. J Neurol. 2010;257(1):72–78.
51. Ko JH, et al. Parkinson’s disease: increased motor network activity in the absence of movement. J Neurosci. 2013;33(10):4540–4549.
52. Mure H, et al. Improved sequence learning with subthalamic nucleus deep brain stimulation: evidence for treatment-specific network modulation. J Neurosci. 2012;32(8):2804–2813.
53. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatr. 1992;55(3):181–184.
54. Tzourio-Mazoyer N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15(1):273–289.
55. Chow GC. Tests of equality between sets of coefficients in two linear regressions. Econometrica. 1960;28(3):591–605.
56. Burnham KP, and Anderson DR. Model Selection and Multimodel Inference. New York, New York, USA: Springer Verlag; 2002.
57. Spetsieris P, et al. Identification of disease-related spatial covariance patterns using neuroimaging data. J Vis Exp. 2013;(76).